83 related articles for article (PubMed ID: 24495562)
1. The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment.
Linares OA; Daly D; Stefanovski D; Boston RC
Med Hypotheses; 2014 Mar; 82(3):390-4. PubMed ID: 24495562
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
4. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of oxycodone: a narrative literature review.
Umukoro NN; Aruldhas BW; Rossos R; Pawale D; Renschler JS; Sadhasivam S
Pharmacogenomics; 2021 Apr; 22(5):275-290. PubMed ID: 33728947
[TBL] [Abstract][Full Text] [Related]
6. Oxycodone's Unparalleled Addictive Potential: Is it Time for a Moratorium?
Remillard D; Kaye AD; McAnally H
Curr Pain Headache Rep; 2019 Feb; 23(2):15. PubMed ID: 30820686
[TBL] [Abstract][Full Text] [Related]
7. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Linares OA; Fudin J; Daly AL; Boston RC
Clin J Pain; 2015 Dec; 31(12):1026-35. PubMed ID: 25621429
[TBL] [Abstract][Full Text] [Related]
8. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy.
Davis MP; Varga J; Dickerson D; Walsh D; LeGrand SB; Lagman R
Support Care Cancer; 2003 Feb; 11(2):84-92. PubMed ID: 12560936
[TBL] [Abstract][Full Text] [Related]
9. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics.
Pöyhiä R; Vainio A; Kalso E
J Pain Symptom Manage; 1993 Feb; 8(2):63-7. PubMed ID: 8492004
[TBL] [Abstract][Full Text] [Related]
10. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
11. Oxycodone recycling: a novel hypothesis of opioid tolerance development in humans.
Linares OA; Fudin J; Schiesser WE; Linares AD; Boston RC
Med Hypotheses; 2014 Sep; 83(3):326-31. PubMed ID: 24986643
[TBL] [Abstract][Full Text] [Related]
12. Oxycodone's mechanism of action and potency differences after spinal and systemic routes of administration.
Smith MT; Edwards SR; Nielsen CK
Anesthesiology; 2007 May; 106(5):1063-4; author reply 1064-5. PubMed ID: 17457147
[No Abstract] [Full Text] [Related]
13. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
14. Effects of oxycodone pharmacogenetics on postoperative analgesia and related clinical outcomes in children: a pilot prospective study.
Aruldhas BW; Quinney SK; Packiasabapathy S; Overholser BR; Raymond O; Sivam S; Sivam I; Velu S; Montelibano A; Sadhasivam S
Pharmacogenomics; 2023 Mar; 24(4):187-197. PubMed ID: 36946298
[No Abstract] [Full Text] [Related]
15. Relative addictive potential of opioid analgesic agents.
Connors NJ; Mazer-Amirshahi M; Motov S; Kim HK
Pain Manag; 2021 Mar; 11(2):201-215. PubMed ID: 33300384
[TBL] [Abstract][Full Text] [Related]
16. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic potential of psychiatric medications and CYP2D6.
Foley KF; Quigley DI
MLO Med Lab Obs; 2010 Jan; 42(1):32-4. PubMed ID: 20180465
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
19. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
20. Relevance of deficient CYP2D6 in opiate dependence.
Mikus G; Mörike K; Griese EU; Klotz U
Pharmacogenetics; 1998 Dec; 8(6):565-8. PubMed ID: 9918141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
